Reportedly, under the purchase order, Sinovac is required to deliver an additional 8.57 million doses of Panflu1 (15ug/0.5ml) to the Chinese Central Government, of which 2.33 million doses are expected to be delivered before March 15, 2010. The balance of 6.23 million doses to be stockpiled by the government in Sinovac’s warehouse facility.
In aggregate, the company has received orders of 21.06 million doses of Panflu1 from the Chinese government, and 10.23 million doses of Panflu1 have been delivered to date for the Chinese vaccination campaign.
In 2009, Sinovac has completed the expansion of its production line used to manufacture the seasonal influenza, H1N1 and H5N1 vaccines, thereby increasing its annual production capacity by approximately 60%.
Weidong Yin, chairman, president and CEO of Sinovac, said: “This fifth order from the Chinese Central Government demonstrates Sinovac’s continuing ability to complete its national H1N1 vaccine stockpiling tasks in a timely manner. The production capacity expansion has continued to serve its purpose in positioning Sinovac to operate even more efficiently towards our goal of providing citizens of China with affordable, international-quality vaccines.”